BEXIMCO PHARMACEUTICALS LIMITED

Group Members: Group Members:

Sakib Md Shafiuddin
Rahnuma Raihan Shuchi
Khalid Ahasan Chowdhury

Largest eporters of medicine in !angladesh Largest eporters of medicine in !angladesh

A local company with a global "ision A local company with a global "ision
-
-
An emerging globally competiti"e industry An emerging globally competiti"e industry

!eimco boasts world#class facilities !eimco boasts world#class facilities

Core $alues of !eimco %harmaceuticals Core $alues of !eimco %harmaceuticals

# some Key &acts # some Key &acts

'ew product and ser"ice offerings ( 'ew product and ser"ice offerings (
international recognition international recognition

Research ( )e"elopment: key to global Research ( )e"elopment: key to global

competence competence

!eimco # Staying ahead of the game !eimco # Staying ahead of the game
# some statistical data # some statistical data
Competitive Advantages and the
ways it changes over time:

Distinguished operational capability

In 1980 it was small in operation but big in
dreams and passionate with its vision -
building a healthier tomorrow where people
will live longer, healthier and happier. Its
activities have always been centered on
developing core competencies to deliver the
best in the industry ensuring superior value
and return to customers.

Consistently delivering high quality

products
Today, the name e!imco "harma# has become
synonymous with $trust% and $reliability%. &uality
is its relentless passion. &uality is ingrained in
our values and in all that it does. e!imco
"harma%s business processes and practices are
designed to achieve 'uality results that would
meet the e!pectations o( patients and physicians
by getting the highest 'uality products, and o(
shareholders and sta)eholders through achieving
returns.

Professional Management Capability

e!imco "harma is the pioneer in implementing
corporate governance to pro(essionally run a company in
angladesh. e!imco "harma provides an environment
which (osters creativity, innovation, sel(-development
and entrepreneurship.

Adopting innovation in manufacturing process

e!imco "harma has always been the pioneer in
adopting innovative technologies that introduced
both sophistication and scale in our business
processes. It also (ocuses on improving
manu(acturing e((iciency to meet the challenge o(
maintaining the bottom line o( the business in an
ever-changing competitive mar)et place.

Sales & Mareting capability focused on brand

building
The ma*or source o( competitive advantages o( e!imco
"harma is its sales and mar)eting team. Its mar)eting
team is composed o( innovative people (rom diverse
discipline. ecause o( the innovative + creative approach
adopted by its mar)eting team, it has been able to
create many vibrant brands li)e ,apa, ,eoceptin--,
.mdocal, ,eo(lo!in, Tycil, /mastin, .0masol, e!itrol-1,
.tova, e!tram 2old etc. In(act, the ability o( its sales +
mar)eting team to di((erentiate our brands even in a
crowded generic mar)et is e!imco "harma%s ma*or
competitive advantage.

!"perience in foreign marets

e!imco "harma always too) the leading, proactive and

pioneering role in e!porting pharmaceuticals (rom
angladesh

It is the pioneer in e!porting ."Is, I3 1luids and hi-tech

speciali0ed products.

It is the (irst pharmaceutical company in angladesh to

enter 4I5 countries.

It is also pioneer to enter .(rican + 6uropean mar)ets.

It is the only company in angladesh to supply medicines

to -a((les 7ospital and 88 9omen + 4hildren 7ospital o(
5ingapore.

#uture growth potential

Domestic and existing expot ma!ets
Its past and present per(ormances clearly suggest
that it has ample scope to grow even in the domestic
as well as in our e!isting e!port mar)ets.
e!imco "harma has already identi(ied some
attractive niche mar)ets where the investment is
negligible as compared to its e!pected returns in
terms o( pro(itability. /nce the new /5: ;/ral 5olide
:osage< plant is operational and it has the capacity,
con(idently, it will be able to capitali0e on these
opportunities and increase its mar)et share in the
domestic mar)et as well as in other e!isting e!port
mar)ets.

'ew eport markets

6ach year patents on pharmaceutical products e!pire
with annual sales worth billions o( dollars. :ata
monitor estimates that there are bloc)buster drugs
coming o((-patent by =00> which have sales in e!cess
o( ?5 @8= billion.
This will be one o( the )ey (actors which will help
drive generic pharmaceutical growth over the ne!t
decade. e!imco "harma is see)ing (or position to
ta)e advantage o( this growing generic mar)et by
regularly introducing new products in its e!isting and
new mar)ets. Its low manu(acturing cost will provide
a competitive edge over our global competitors in
any international generic pharmaceutical mar)et.

Contract Manufacturing
4ost o( medication is becoming a ma*or concern even in the
developed countries. This particular issue coupled with severe
price competition (rom the generic manu(acturers has prompted
a number o( giant multinational companies to shi(t or outsource
their production (rom developed to developing and less
developed countries, because o( huge cost advantage. It is
believed that the world pharmaceutical mar)et will continue to
see more consolidation than ever across the entire value chain o(
the pharmaceutical business. ig companies will continue to loo)
(or suitable partners in their supply chain management in order
to reduce their cost o( production.
e!imco "harma has always operated li)e a $multinational% in
terms o( pro(essionalism and in(rastructure so as to build the
plat(orm to become a global player. Aanagement has adhered to
international regulatory standards which is more pre(erable to
our international partners.
Sales $rowth %ate
Growth Rates
(%) 2012 2011 2010 2009 2008 STDEV
Sales
14.2321
7 -2.84395
11.2801
7
38.4701
2
10.0223
5 17.3734379
!"e# $sset
11.2376
6 5.54%%7
14.8395
1
20.4081
3
4.15%33
3
7.73742924
2
Operating Cost
28.2325
8 -0.99797 18.03202 78.44515 17.45111 34.62185398
Current Asset
10.9518
3 -12.9153 -3.96058 41.4457 19.23751 24.43050677
Retained Earning
16.6488
4 3.786453 16.55193 41.04439 5.212577 17.23738
Sare !ri"e
24.3052
5 9.683426 -7.09343 -37.2421 131.8731 74.29356
#on-"urrent
$ia%i&it'
1.62443
5 44.54765 -11.5582 -23.4905 -3.00112 29.82361
Current $ia%i&it'
12.7051
9 -35.5876 1.023103 47.03386 38.35137 37.88072
E!S
8.42882
1 -25.0608 -35.3774 35.03185 59.12162 45.89124
2007 2008 2009 2010 2011 2012
(Growth Rate & 14.23%)
(i)ed Assets
9*029*643*4
82
10*314*561*
749
11*782*323*
886
13*458*948*
575
15*374*156*9
58
17*561*899*4
93
Current Assets
2*923*775*4
58
3*339*828*7
06
3*815*086*3
30
4*357*973*1
15
4*978*112*69
0
5*686*498*12
5
+ota& Assets
11*953*418*
940
13*654*390*
455
15*597*410*
217
17*816*921*
691
20*352*269*6
47
23*248*397*6
18
#on-Current $ia%i&ities
2*074*506*3
57
2*369*708*6
12
2*706*918*1
47
3*092*112*5
99
3*532*120*22
2
4*034*740*93
0
Current $ia%i&ities
1*627*972*9
36
1*859*633*4
85
2*124*259*3
30
2*426*541*4
32
2*771*838*27
8
3*166*270*86
5
+ota& $ia%i&ities
3*702*479*2
93
4*229*342*0
96
4*831*177*4
77
5*518*654*0
32
6*303*958*50
0
7*201*011*79
5
Sare !re,iu,
1*489*750*0
00
1*489*750*0
00
1*489*750*0
00
1*489*750*0
00
1*489*750*00
0
1*489*750*00
0
E)"ess o- .ssue !ri"e o/er (a"e 0a&ue
o- 12Rs
1*689*636*9
58
1*689*636*9
58
1*689*636*9
58
1*689*636*9
58
1*689*636*95
8
1*689*636*95
8
Capita& Reser/e on 3erger 294*950*950 294*950*950 294*950*950 294*950*950 294*950*950 294*950*950
+a)-4o&ida' Reser/e 442*354*953 505*302*063 577*206*546 659*343*038 753*167*552 860*343*295
Retained Earning
3*189*176*3
56
3*642*996*1
51
4*161*394*5
04
4*753*560*9
42
5*429*992*66
4
6*202*680*62
0
.ssued Sare Capita&
1*145*070*4
30
1*308*013*9
52
1*494*144*3
38
1*706*761*0
77
1*949*633*17
8
2*227*065*97
9
Sareo&ders5 E6uit'
8*250*939*6
47
8*930*650*0
74
9*707*083*2
96
10*594*002*
964
11*607*131*3
02
12*764*427*8
02
Sareo&ders5 E6uit' 7 $ia%i&ities
11*953*418*
940
13*159*992*
171
14*538*260*
772
16*112*656*
996
17*911*089*8
02
19*965*439*5
97
Excess(Required) Fund 0
8494*398*28
49
81*059*149*4
449
81*704*264*6
959
82*441*179*8
459
83*282*958*0
219
Pro #orma balance sheet
Bangladesh's largest Pharmaceutical Companies (by sales '08)
Top 10 Sales in $ n
S!uare $1"8#$
%ncepta $ &'#1
Be(imco $ )*#0
+cme $ ",#"
-s.aye/ $ "'#1
+C% $ "1#"
0psonin $ '*#$
1enata $ '*#1
+ristopharma $ '8#8
2rug %nternational $ '"#)
Maret Shares

5ponsors and :irectors o( &P' have =0.BCD,

/ther (inancial and non (inancial Institutes

have 11.=ED,

1oreign investors have CC.FED

"ublic have CF.B>D o( shares o( the company.

Company Shares